Literature DB >> 29502986

Diverse effects of interleukin-22 on pancreatic diseases.

Xiuyun Xuan1, Zhiqiang Tian2, Mengjie Zhang3, Jian Zhou3, Weiwu Gao3, Yi Zhang3, Yue Zhang4, Bo Lei5, Bing Ni3, Yuzhang Wu6, Weiping Fan7.   

Abstract

Interleukin-22 (IL-22) is involved in the development of lymphocytes and serves as a rapid and early source of the effector cytokines that are released in response to pathogen-induced changes in the microenvironment. Recent research has implicated IL-22 as a potential contributing factor to the spectrum of inflammation-related pancreatic diseases, particularly pancreatitis, fibrosis, carcinoma and diabetes. In this review, we summarize the current knowledge on the roles of IL-22 in the various pancreatic pathogenesis, providing insights into the underlying cellular and signaling mechanisms that will help guide future research into promising interventional targets with therapeutic potential.
Copyright © 2018 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cytokine; Interleukin-22; Pancreatic cancer; Signal transducer

Mesh:

Substances:

Year:  2018        PMID: 29502986     DOI: 10.1016/j.pan.2018.02.014

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  3 in total

1.  ILC3 cells promote the proliferation and invasion of pancreatic cancer cells through IL-22/AKT signaling.

Authors:  X Xuan; J Zhou; Z Tian; Y Lin; J Song; Z Ruan; B Ni; H Zhao; W Yang
Journal:  Clin Transl Oncol       Date:  2019-06-15       Impact factor: 3.405

2.  IL-22 Signaling in the Tumor Microenvironment.

Authors:  Runqiu Jiang; Beicheng Sun
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  A Double Edged Sword Role of Interleukin-22 in Wound Healing and Tissue Regeneration.

Authors:  Tanzeela Arshad; Fizzah Mansur; Richard Palek; Sobia Manzoor; Vaclav Liska
Journal:  Front Immunol       Date:  2020-09-17       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.